9 results about "Bone morphogenetic protein 2" patented technology

The invention discloses siRNA (small interfering Ribonucleic Acid) of targeted bone morphogenetic protein 2, modified siRNA and application of the siRNA. According to the invention, siRNA drug design is carried out by taking the BMP2 gene as a target gene to obtain a series of siRNAs, siRNAs capable of effectively silencing the mRNA expression level of the BMP2 gene are screened from the siRNAs, and part of siRNA sequences can even silence the mRNA level of the BMP2 gene to about 25%. The siRNA sequence is further modified, wherein phosphorylation or phosphorylation analogue modification, skeleton modification, sugar ring modification and basic group modification are carried out on the 5'terminal of the sequence, or cholesterol molecule modification is carried out on the end group of the siRNA. The siRNA sequence is further subjected to cholesterol modification to obtain a human-mouse homologous sequence of the targeted BMP2 gene, and the in-vivo silencing activity of the BMP2 target spot is further researched in a mouse experimental model subsequently.

This application provides a composition containing PENK protein and its application in promoting osteoblast osteogenic differentiation. Compared with the prior art, this application has the following advantages: The pro-PENK recombinant protein and the PENK-containing composition provided in this application, after being applied to cells with osteogenic potential, enhance osteogenic performance through interaction with CBFB protein, and can significantly promote osteogenic differentiation. Compared with the existing bone morphogenetic protein 2 (BMP recombinant protein), the osteogenic effect is superior. Furthermore, experiments have verified that the osteogenic differentiation effect of pro-PENK recombinant protein on osteoblasts is dose-dependent. This application further verifies that the combined use of low doses of PENK recombinant protein and BMP recombinant protein has a more significant cellular osteogenic effect than the use of either at high doses alone.

This document relates to methods and materials for using 4-aminopyridine (4-AP) and / or one or more derivatives of 4-AP. For example, a composition containing 4-AP and / or one or more derivatives of 4-AP can be administered (e.g., orally administered) to a mammal to increase a level of bone morphogenetic protein 2 (BMP-2) polypeptides within the mammal. For example, a composition containing 4-AP and / or one or more derivatives of 4-AP can be administered (e.g., orally administered) to a mammal having bone loss to increase the level of BMP-2 within the mammal, thereby treating the mammal's bone loss.

The invention provides a method for inducing ankylosing spondylitis synovial fibroblast osteogenesis in vitro, and belongs to the technical field of cell culture, the ankylosing spondylitis hip joint synovial fibroblast is induced in vitro by using 100ng / mL of tumor necrosis factor-alpha (TNF-alpha) and 100ng / mL of bone morphogenetic protein 2 (BMP-2), and the ankylosing spondylitis hip joint synovial fibroblast can be converted into osteoblasts 12 days after induction. The ankylosing spondylitis synovial fibroblast osteogenesis is specifically induced, the interference of non-target cells is reduced, and the accuracy and reliability of the experiment are improved; the method disclosed by the invention is simple, strong in operability and good in controllability, lays a foundation for research on pathogenesis of new bone formation of ankylosing spondylitis, can greatly shorten the experimental period, and has better application prospects compared with traditional BMP-2 and TGF-beta induced fibroblasts. The osteogenesis model constructed by the method is closer to an osteogenesis mechanism of ankylosing spondylitis and is higher in conversion efficiency.

The invention provides a composition containing PENK protein and application of the composition in promoting osteogenic differentiation by osteoblasts. Compared with the prior art, the proenkephalin PENK recombinant protein and the composition containing PENK have the advantages that after being applied to cells with osteogenic potential, the proenkephalin PENK recombinant protein and the composition containing PENK interact with CBFB protein to improve osteogenic performance, the effect of promoting osteogenic differentiation can be obviously achieved, and the proenkephalin PENK recombinant protein and the composition containing PENK have good application prospects. Compared with existing bone morphogenetic protein 2 (BMP) recombinant protein, the proenkephalin PENK recombinant protein is more excellent in osteogenesis promoting effect, and experiments prove that the osteogenic differentiation promoting effect of the proenkephalin PENK recombinant protein is dose-dependent. The application further verifies that the combined use of low doses of the PENK recombinant protein and the BMP recombinant protein has a more remarkable cell osteogenesis promoting effect compared with the independent use of high doses of the PENK recombinant protein and the BMP recombinant protein.

Provided are unique affibodies specific for bone morphogenetic protein 2 (BMP-2), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), platelet-derived growth factor (PDGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), inteleukin-4 (IL-4), and glial derived neurotrophic factor (GDNF), and well as hydrogels that include the affibodies and the corresponding protein. Also provided are methods of using the hydrogels, for example to treat bone injury, wounds, and neuron injury. In some examples, the hydrogel includes at least two different affibodies specific for the same protein, but have different disassociation constants (KD). Also provided are methods of using the affibodies to treat a disease, wound, injury, or cancer.

Provided are dual-affinity fusion proteins including an affibody domain specific for a therapeutic protein, and including a localization domain specific for a structural bone component. The therapeutic protein can include bone morphogenetic protein 2 (BMP-2), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), platelet-derived growth factor (PDGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), or glial derived neurotrophic factor (GDNF). Also provided are compositions that include the dual-affinity fusion proteins, affibodies and the corresponding therapeutic proteins, and / or a medical material used to treat a wound, or a bone or cartilage injury or disease. Also provided are methods of using the compositions, for example to treat bone injuries, bone diseases, cartilage injuries, cartilage diseases, and wounds. In some examples, the composition includes at least two different dual-affinity fusion proteins specific for the same therapeutic protein, but have different disassociation constants (KD).

This document provides methods and materials involved in promoting bone growth. For example, this document provides vectors designed to express (a) a nucleotide sequence encoding a bone morphogenetic protein 2 (BMP2) polypeptide and / or (b) a nucleotide sequence encoding an interleukin-1 receptor antagonist (IL-1Ra) polypeptide for promoting bone growth. In some cases, one or more vectors provided herein can be administered to a mammal (e.g., a human) having a disease, disorder, or condition associated with bone loss to treat the mammal. For example, a population of a single vector provided herein can be used to increase expression of a BMP2 polypeptide and an IL-1Ra polypeptide by cells within a mammal (e.g., a human) having a disease, disorder, or condition associated with bone loss to promote bone growth within the mammal.

An apparatus for stimulation of tissue regeneration at a site in tissue of a subject, the apparatus comprising: an outer sleeve having a tissue receiving end, a pressing member receiving end opposite the tissue receiving end, and an internal chamber configured for receiving the tissue; a pressing member; an inner sleeve disposed within the outer sleeve, the inner sleeve having an end for receiving the site of the tissue for regeneration, an engagement receiving end, opposite the end for receiving the site of the tissue for regeneration, for engaging the pressing member, and an internal chamber configured for receiving the site of the tissue for regeneration, wherein the internal chamber of the inner sleeve comprises a therapeutic composition, wherein the therapeutic composition comprises a growth factor, wherein the growth factor comprises (i) bone morphogenetic protein 2 (BMP2), or (ii) a bone morphogenetic protein and a vascular endothelial growth factor (VEGF).